IQVIA Holdings Inc. (IQV) is listed on NYSE and operates in the Medical - Diagnostics & Research industry (Healthcare sector).
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and pa...
| Rating | Analysts |
|---|---|
| Strong Buy | 1 |
| Buy | 36 |
| Hold | 6 |
| Sell | 1 |
| Strong Sell | 0 |
IQVIA Holdings Inc., headquartered in Durham, North Carolina, provides analytics, technology solutions, and clinical research services to the life sciences industry globally. The company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers cloud-based applications, real-world evidence solutions, and consulting services, focusing on advanced analytics and commercial process outsourcing. It also provides performance metrics related to pharmaceutical sales, prescribing trends, and medical treatment across various channels.
The Research & Development Solutions segment delivers project management, clinical monitoring, and trial support services, including virtual trials and strategic planning. It also offers laboratory services such as genomic, bioanalytical, and vaccine research.
The Contract Sales & Medical Solutions segment focuses on healthcare provider and patient engagement, as well as scientific strategy and medical affairs services. IQVIA serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company, originally known as Quintiles IMS Holdings, Inc., was founded in 1982 and rebranded to IQVIA Holdings Inc. in November 2017.
Over the past three fiscal years, the company has demonstrated consistent revenue growth, with a CAGR of 4.3%, increasing from $14.98 billion in 2023 to $16.31 billion in 2025. This growth was accompanied by a steady increase in earnings per share (EPS), which rose at a CAGR of 3.7%, from $7.29 to $7.84. Despite the revenue growth, the company's gross margin experienced a significant compression, decreasing by 8.7 percentage points from 34.96% to 26.28%, which suggests rising costs or pricing pressures. However, operating margins showed a slight improvement, increasing by 0.8 percentage points to 14.02%, indicating some degree of operating leverage. The company has been effective in generating cash, with free cash flow (FCF) growing at a robust CAGR of 16.9%, from $1.5 billion to $2.05 billion, and FCF margins improving by 2.6 percentage points to 12.58%. This strong cash generation is further supported by a cash conversion ratio (CCR) of 1.95, indicating that earnings are well-backed by cash. The company's capital efficiency has been bolstered by a consistent decrease in capex intensity, now at 3.7%, and a reduction in the cash conversion cycle (CCC) to just 6 days, reflecting improved working capital management. Notably, the company has also enhanced shareholder value through a 6.9% reduction in share count, amplifying per-share gains. However, liquidity remains a concern with a current ratio below 1, suggesting potential challenges in meeting short-term obligations.
Recent news for IQVIA Holdings Inc. centers around its Q1 2026 earnings and financial activities. Although specific figures from the earnings call are not detailed, the company held its Q1 earnings call on May 10, with highlights covered by MarketBeat. Additionally, Zacks Investment Research provided insights into key metrics from the Q1 earnings on May 6. In related financial activities, Artisan Value Fund disclosed its Q1 2026 portfolio activity on May 5, which included IQVIA. Analyst perspectives on IQVIA were also highlighted, with Zacks Investment Research identifying the company as a top value stock for the long term on May 12. Institutional trading activity showed significant movements, with Calamos Wealth Management LLC investing approximately $11.93 million in IQVIA, acquiring 52,910 shares. Concurrent Investment Advisors LLC also increased its holdings, purchasing 3,161 shares valued at $2.69 million. Conversely, the Arizona State Retirement System sold 4,548 shares, reducing its position. These transactions reflect ongoing portfolio adjustments by institutional investors, which are part of routine management and do not necessarily indicate changes in the company's outlook.
IQVIA operates in the healthcare and life sciences industry, which is currently experiencing a dynamic phase marked by technological advancements, particularly in AI, and regulatory changes. The industry is seeing a stabilization after years of macroeconomic challenges, including policy-driven headwinds and funding constraints. Management identifies AI as a significant tailwind, enhancing demand for their services, while macroeconomic uncertainties and regulatory shifts pose potential headwinds. Over the calls, the emphasis on AI's role in driving demand has remained consistent, with management viewing it as a catalyst for growth rather than a disruptive threat.
IQVIA's recent performance has been robust, with Q1 2026 revenue and adjusted EPS exceeding guidance. The company reported strong organic growth in both Commercial and R&D Solutions, driven by increased demand for AI-enabled services and a rebound in client spending. Management expressed satisfaction with the acceleration of organic revenue growth, particularly in Commercial Solutions, where AI-driven innovations are gaining traction. Concerns were noted regarding the mix of service bookings and pass-throughs, which affected the book-to-bill ratio. The narrative across calls highlighted a shift from macroeconomic stabilization to leveraging AI for growth, with management confident in the underlying demand dynamics.
IQVIA's growth strategy focuses on expanding AI capabilities, enhancing data-driven solutions, and pursuing strategic collaborations. Investments are being made in AI infrastructure, R&D, and strategic partnerships, such as with NVIDIA and AWS, to bolster their competitive edge. Management claims a strong competitive advantage through proprietary data and domain expertise, which they argue are critical for AI-driven healthcare solutions. Risks include potential regulatory changes and competitive pressures, particularly from other CROs and tech companies entering the healthcare space. Analysts questioned the impact of AI on traditional service models, but management reiterated AI as an opportunity to enhance, not replace, existing services. The strategy appears promising, but execution risks and market dynamics warrant cautious optimism.
Comparing the two calls, IQVIA has largely delivered on its commitments, with Q1 2026 results exceeding expectations. Management's guidance for revenue and EPS was met, and they raised EPS guidance for the full year. The focus on AI and strategic partnerships was consistent, with progress reported in AI agent deployment. However, the earlier call's emphasis on organizational simplification and segment reporting changes was less prominent in the later call. Overall, management has been consistent in their messaging and delivery, although the impact of AI on margins and service models remains a point of scrutiny.
- Monitor Q2 2026 revenue guidance of $4.28 billion to $4.34 billion and adjusted EPS of $2.98 to $3.08 to assess continued growth momentum.
- Track the deployment and adoption of AI agents across client workflows, as this is a key driver of future service demand and competitive positioning.
- Observe the mix of service bookings versus pass-throughs, as this affects profitability and the book-to-bill ratio, which management has flagged as a non-predictive metric.
- Evaluate the impact of strategic partnerships, such as with AWS and NVIDIA, on expanding AI capabilities and client engagement.
- Assess the stabilization of macroeconomic conditions and funding environments, particularly in biotech, as these influence client spending and R&D investments.